Literature DB >> 18256528

Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells.

Massimo Olivotto1, Persio Dello Sbarba.   

Abstract

Tumors are ecosystems which develop from stem cells endowed with unlimited self-renewal and genetic instability, under the effects of mutagenesis and natural selection imposed by environmental changes. While changes and variations made possible by genetic instability are practically unlimited, the microenvironment progressively reduces those possibilities in the struggle for life imposed by hypoxia and nutrient shortage typical of tumor environments. This entails the tendency to evolve a convergent phenotype resistant to microenvironmental restrictions (first of all hypoxia), which progressively dominates the clonal selection. It is shown that adaptation to hypoxia, rather than being a peculiarity of cancer stem cells, is also a characteristic of normal hematopoietic stem cells, and may thus be described as a general feature of the stem cell phenotype. The metabolic orientation of this phenotype closely resembles the orientation of highly anaplastic ascites hepatomas, showing that, in restricted environments, stem cell recruitment to growth is limited by mitochondrial reoxidation of reducing equivalents produced in folate redox steps connected with purine synthesis. Finally, a review of earlier research into glucose metabolism in cancer leads to the reinterpretation of Warburg's aerobic glycolysis as a defence mechanism which disposes of glycolytic products able to negatively interfere with the crucial role of mitochondrial respiration in cell recruitment for growth.

Entities:  

Mesh:

Year:  2007        PMID: 18256528     DOI: 10.4161/cc.7.2.5315

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.

Authors:  Serena Giuntoli; Michele Tanturli; Federico Di Gesualdo; Valentina Barbetti; Elisabetta Rovida; Persio Dello Sbarba
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

Review 2.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

Review 3.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 4.  Organoid development in cancer genome discovery.

Authors:  Dong Gao; Yu Chen
Journal:  Curr Opin Genet Dev       Date:  2015-03-19       Impact factor: 5.578

Review 5.  New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence.

Authors:  M Mimeault; S K Batra
Journal:  Histol Histopathol       Date:  2010-08       Impact factor: 2.303

6.  The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming.

Authors:  Ilaria Marzi; Maria Grazia Cipolleschi; Massimo D'Amico; Theodora Stivarou; Elisabetta Rovida; Maria Cristina Vinci; Silvia Pandolfi; Persio Dello Sbarba; Barbara Stecca; Massimo Olivotto
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 7.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery.

Authors:  Bin-Bing S Zhou; Haiying Zhang; Marc Damelin; Kenneth G Geles; Justin C Grindley; Peter B Dirks
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

8.  Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment.

Authors:  Phuc Van Pham; Ngoc Bich Vu; Thuy Thanh Duong; Tam Thanh Nguyen; Nhung Hai Truong; Nhan Lu Chinh Phan; Tue Gia Vuong; Viet Quoc Pham; Hoang Minh Nguyen; Kha The Nguyen; Nhung Thi Nguyen; Khue Gia Nguyen; Lam Tan Khat; Dong Van Le; Kiet Dinh Truong; Ngoc Kim Phan
Journal:  Onco Targets Ther       Date:  2012-05-07       Impact factor: 4.147

9.  Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.

Authors:  Michele Tanturli; Serena Giuntoli; Valentina Barbetti; Elisabetta Rovida; Persio Dello Sbarba
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

Review 10.  Extracellular molecules involved in cancer cell invasion.

Authors:  Theodora Stivarou; Evangelia Patsavoudi
Journal:  Cancers (Basel)       Date:  2015-01-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.